Skip to main content

Day One Biopharmaceuticals, Inc. (DAWN)

NASDAQ: DAWN · IEX Real-Time Price · USD
23.61 -0.73 (-3.00%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap1.51B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out22.66M
EPS (ttm)-29.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume51,381
Open24.33
Previous Close24.34
Day's Range23.10 - 24.34
52-Week Range17.19 - 28.70
Betan/a
Analystsn/a
Price Target34.67 (+46.8%)
Est. Earnings DateOct 25, 2021

About DAWN

Day One is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, we focus our clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. Our lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. ...

IndustryBiotechnology
IPO DateMay 27, 2021
CEOJeremy Bender, Ph.D., M.B.A.
Employees29
Stock ExchangeNASDAQ
Ticker SymbolDAWN
Full Company Profile

Financial Performance

Financial Statements

News

Day One Appoints Jaa Roberson as Chief People Officer

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...

1 week ago - GlobeNewsWire

Day One Appoints Scott Garland to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

1 month ago - GlobeNewsWire

Day One Reports Second Quarter 2021 Financial Results and Corporate Progress

DAY101 Granted Rare Pediatric Disease Designation from FDA

1 month ago - GlobeNewsWire

Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma

SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for p...

3 months ago - GlobeNewsWire

Day One Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchas...

SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing tar...

3 months ago - GlobeNewsWire

Day One Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targ...

3 months ago - GlobeNewsWire

Day One Biopharmaceuticals IPO Registration Document (S-1)

Day One Biopharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC